干细胞治疗肝硬化合并银屑病患者1例报道及文献复习

doi:10.3760/cma.j.issn.1007-1245.2024.04.025

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (4): 638-640.DOI: 10.3760/cma.j.issn.1007-1245.2024.04.025

干细胞治疗肝硬化合并银屑病患者1例报道及文献复习

王凤梅张文华陈多兆白兆娟

甘肃省武威肿瘤医院肝病科，武威　733000

收稿日期:2023-10-19 出版日期:2024-02-01 发布日期:2024-03-07
通讯作者: 王凤梅，Email：wangfm1304@163.com
基金资助:
武威市科技局科技计划项目（ww2001010、ww2101113）

Stem cell therapy for a patient with cirrhosis and psoriasis: a case report and literature review

Wang Fengmei, Zhang Wenhua, Chen Duozhao, Bai Zhaojuan

Department of Hepatology, Gansu Wuwei Tumour Hospital, Wuwei 733000, China

Received:2023-10-19 Online:2024-02-01 Published:2024-03-07
Contact: Wang Fengmei ,Email: wangfm1304@163.com
Supported by:
Science and Technology Plan Project of Wuwei Science and Technology Bureau (ww2001010, ww2101113)

摘要/Abstract

摘要：

银屑病是一种慢性、复发性疾病。临床表现为鳞屑性红斑或斑块，呈局限或广泛分布，病情反复，严重影响患者生活质量。乙型肝炎肝硬化失代偿期可能出现多种并发症，如腹水、消化道出血等。间充质干细胞（mesenchymal stem cells，MSCs）是一种多能非造血基质细胞，存在于不同的身体组织中。近年来，MSCs被尝试应用于肝硬化失代偿期以及银屑病的患者中，部分患者取得了较好的效果。本例乙肝肝硬化失代偿期合并银屑病患者，应用干细胞治疗取得了较好的疗效，为此类患者的治疗提供了一定的参考价值。

关键词:

银屑病, 肝硬化, 失代偿期, 干细胞治疗

Abstract:

Psoriasis is a chronic, recurrent disease characterized by squamous erythema or plaques, which are localized or widely distributed. The condition is recurrent and seriously affects patients' quality of life. During the decompensated phase of hepatitis B cirrhosis, various complications may occur, such as ascites and gastrointestinal bleeding. Mesenchymal stem cells (MSCs) are pluripotent non hematopoietic stromal cells that exist in different body tissues. In recent years, they have been attempted to be applied in patients with decompensated liver cirrhosis and psoriasis, and some patients have achieved good results. In this paper, a patient with decompensated liver cirrhosis and psoriasis was treated by stem cell therapy, and he achieved good results, which provided a certain reference value for the treatment of such patients.

Key words:

Psoriasis, Liver cirrhosis, Decompensated phase, Stem cell therapy

王凤梅张文华陈多兆白兆娟.

干细胞治疗肝硬化合并银屑病患者1例报道及文献复习 [J]. 国际医药卫生导报, 2024, 30(4): 638-640.

Wang Fengmei, Zhang Wenhua, Chen Duozhao, Bai Zhaojuan.

Stem cell therapy for a patient with cirrhosis and psoriasis: a case report and literature review [J]. International Medicine and Health Guidance News, 2024, 30(4): 638-640.

参考文献

[1] Rendon A, Schäkel K. Psoriasis pathogenesis and treatment[J]. Int J Mol Sci, 2019, 20(6):1475. DOI: 10.3390/ijms20061475.
[2] 陆子轩,吴建华.胞外囊泡在银屑病中的研究进展[J].中国麻风皮肤病杂志,2023,39(3):218-222.DOI:10.12144/zgmfskin202303218.
[3] Liu Y, Dong Y, Wu X, et al. Identification of immune microenvironment changes and the expression of immune-related genes in liver cirrhosis[J]. Front Immunol, 2022, 13:918445. DOI: 10.3389/fimmu.2022.918445.
[4] D'Amico G, Morabito A, D'Amico M, et al. Clinical states of cirrhosis and competing risks[J]. J Hepatol, 2018, 68(3):563-576. DOI: 10.1016/j.jhep.2017.10.020.
[5] Diotallevi F, Di Vincenzo M, Martina E, et al. Mesenchymal stem cells and psoriasis: systematic review[J]. Int J Mol Sci, 2022, 23(23):15080. DOI: 10.3390/ijms232315080.
[6] Liang N, Chang W, Peng A, et al. Dermal mesenchymal stem cells from psoriatic lesions stimulate HaCaT cell proliferation, differentiation, and migration via activating the PI3K/AKT signaling pathway[J]. Dermatology, 2022, 238(2):283-291. DOI: 10.1159/000515767.
[7] 中华医学会医学工程学分会干细胞工程专业学组,Medical Engineering Society of Chinese Medical Association.干细胞移植规范化治疗肝硬化失代偿的专家共识(2021)[J].临床肝胆病杂志,2021,37(7):1540-1544. DOI:10.3969/j.issn.1001-5256.2021.07.012.
[8] Chang W, Liang N, Cao Y, et al. The effects of human dermal-derived mesenchymal stem cells on the keratinocyte proliferation and apoptosis in psoriasis[J]. Exp Dermatol, 2021, 30(7):943-950. DOI: 10.1111/exd.14353.
[9] Orciani M, Campanati A, Salvolini E, et al. The mesenchymal stem cell profile in psoriasis[J]. Br J Dermatol, 2011, 165(3):585-592. DOI: 10.1111/j.1365-2133.2011.10438.x.
[10] Campanati A, Orciani M, Consales V, et al. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis[J]. Arch Dermatol Res, 2014, 306(10):915-920. DOI: 10.1007/s00403-014-1493-3.
[11] Liu R, Yang Y, Yan X, et al. Abnormalities in cytokine secretion from mesenchymal stem cells in psoriatic skin lesions[J]. Eur J Dermatol, 2013, 23(5):600-607. DOI: 10.1684/ejd.2013.2149.
[12] Wang Y, Liang Y, Li J, et al. Expression and functional regulation of gap junction protein connexin 43 in dermal mesenchymal stem cells from psoriasis patients[J]. Acta Histochem, 2020, 122(4):151550. DOI: 10.1016/j.acthis.2020.151550.
[13] Li J, Xing J, Lu F, et al. Psoriatic dermal-derived mesenchymal stem cells reduce keratinocyte junctions, and increase glycolysis[J]. Acta Derm Venereol, 2020, 100(8):adv00122. DOI: 10.2340/00015555-3480.
[14] Shin TH, Kim HS, Choi SW, et al. Mesenchymal stem cell therapy for inflammatory skin diseases: clinical potential and mode of action[J]. Int J Mol Sci, 2017, 18(2):244. DOI: 10.3390/ijms18020244.
[15] Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells[J]. Blood, 2005, 105(7):2821-2827. DOI: 10.1182/blood-2004-09-3696.
[16] English K, Ryan JM, Tobin L, et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(high) forkhead box P3+ regulatory T cells[J]. Clin Exp Immunol, 2009, 156(1):149-160. DOI: 10.1111/j.1365-2249.2009.03874.x.
[17] Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli[J]. Blood, 2002, 99(10):3838-3843. DOI: 10.1182/blood.v99.10.3838.
[18] Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses[J]. Blood, 2005, 105(4):1815-1822. DOI: 10.1182/blood-2004-04-1559.
[19] Paganelli A, Tarentini E, Benassi L, et al. Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review[J]. Clin Exp Dermatol, 2020, 45(7):824-830. DOI: 10.1111/ced.14269.
[20] Chen Y, Yu Q, Hu Y, et al. Current research and use of mesenchymal stem cells in the therapy of autoimmune diseases[J]. Curr Stem Cell Res Ther, 2019, 14(7):579-582. DOI: 10.2174/1574888X14666190429141421.
[21] Orciani M, Campanati A, Caffarini M, et al. T helper (Th)1, Th17 and Th2 imbalance in mesenchymal stem cells of adult patients with atopic dermatitis: at the origin of the problem[J]. Br J Dermatol, 2017, 176(6):1569-1576. DOI: 10.1111/bjd.15078.

干细胞治疗肝硬化合并银屑病患者1例报道及文献复习

Stem cell therapy for a patient with cirrhosis and psoriasis: a case report and literature review

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

[1]	高立娟肖欣戴国栋关春迪于海生. 肝硬化腹水并脐疝嵌顿1例报道及文献复习 [J]. 国际医药卫生导报, 2023, 29(7): 998-1001.
[2]	尹金阁王栓铎. 生长抑素针联合三腔两囊管治疗肝硬化合并EGVB患者的效果 [J]. 国际医药卫生导报, 2023, 29(5): 655-659.
[3]	付志鹏郑盛杨涓. 肝硬化患者营养评价方法研究进展 [J]. 国际医药卫生导报, 2023, 29(23): 3341-3344.
[4]	孔敏靳欣赵琴. 微信群为基础的短视频远程干预联合IMB模型在肝硬化患者居家护理效果指导 [J]. 国际医药卫生导报, 2023, 29(18): 2649-2654.
[5]	周兆年郑伟强. 血小板在肝硬化中的研究进展 [J]. 国际医药卫生导报, 2023, 29(12): 1640-1643.
[6]	田昊宫雪莲丁坤. 恩替卡韦联合复方鳖甲软肝片治疗HBeAg阳性失代偿期肝硬化患者的疗效分析 [J]. 国际医药卫生导报, 2023, 29(10): 1404-1408.
[7]	王丽张瑞. 肝硬化患者肠黏膜通透性改变与肝功能分级的关系研究 [J]. 国际医药卫生导报, 2023, 29(1): 105-.
[8]	唐学良张晖凌明强. 肝硬化食管静脉曲张破裂出血的临床特点与危险因素分析[J]. 国际医药卫生导报, 2022, 28(19): 2753-2757.
[9]	张盼盼　王朝阳　鹿璐　燕彦. 早期肠内营养支持在门脉高压行TIPS术后患者中的应用价值[J]. 国际医药卫生导报, 2022, 28(16): 2250-2254.